GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sienna Biopharmaceuticals Inc (OTCPK:SNNAQ) » Definitions » Cash Ratio

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Cash Ratio : 8.77 (As of Sep. 2019)


View and export this data going back to 2017. Start your Free Trial

What is Sienna Biopharmaceuticals Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Sienna Biopharmaceuticals's Cash Ratio for the quarter that ended in Sep. 2019 was 8.77.

Sienna Biopharmaceuticals has a Cash Ratio of 8.77. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Sienna Biopharmaceuticals's Cash Ratio or its related term are showing as below:

SNNAQ's Cash Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.95
* Ranked among companies with meaningful Cash Ratio only.

Sienna Biopharmaceuticals Cash Ratio Historical Data

The historical data trend for Sienna Biopharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sienna Biopharmaceuticals Cash Ratio Chart

Sienna Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18
Cash Ratio
4.92 0.92 9.04 1.99

Sienna Biopharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.63 1.99 2.55 2.36 8.77

Competitive Comparison of Sienna Biopharmaceuticals's Cash Ratio

For the Biotechnology subindustry, Sienna Biopharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sienna Biopharmaceuticals's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sienna Biopharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Sienna Biopharmaceuticals's Cash Ratio falls into.



Sienna Biopharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Sienna Biopharmaceuticals's Cash Ratio for the fiscal year that ended in Dec. 2018 is calculated as:

Cash Ratio (A: Dec. 2018 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=48.526/24.349
=1.99

Sienna Biopharmaceuticals's Cash Ratio for the quarter that ended in Sep. 2019 is calculated as:

Cash Ratio (Q: Sep. 2019 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=11.332/1.292
=8.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sienna Biopharmaceuticals  (OTCPK:SNNAQ) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Sienna Biopharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of Sienna Biopharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.
Executives
Alexander Azoy officer: Chief Financial Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Timothy K. Andrews officer: General Counsel & Secretary 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Iii Frederick Beddingfield director, officer: President & CEO C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Diane Stroehmann officer: See Remarks 30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362
Dennis M Fenton director
Todd Harris director 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Kristina Burow director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert J More director 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Arch Venture Partners Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Headlines

From GuruFocus